Short answer
Solventum (SOLV) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $2.2B (up 2.2% year over year) with net income of $92M.
Q2 2026 key financials · XBRL
- Revenue
- $2.2B
- +2.2% YoY · +10.1% QoQ
- Net income
- $92M
- +2.2% YoY · +607.7% QoQ
- Operating margin
- 8.2%
- Gross margin
- 58.2%
- EPS (diluted)
- $0.53
- +1.9% YoY · +657.1% QoQ
Source: XBRL data from the Solventum (SOLV) Q2 2026 10-Q on SEC EDGAR. USD.
Solventum Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q2 revenue $2.209B, up 2.2% YoY from $2.161B
- Operating margin 8.2% vs 9.9% YoY; cost of product 47.5% vs 51.9%
- Best segment Dental Solutions: revenue $396M, up 17.0%; margin 33.0% vs 28.5%
- Worst segment Health Information Systems: revenue $354M, up 4.4%; clinician productivity declines amid changing market conditions
- Cash $403M vs $878M at December 31; six-month operating cash flow $38M vs $198M, with $350M financing outflows
- Q3 headwind: customer inventory normalization expected after $125M of ERP-related advanced orders in Q2
Risk Factors
- Newly added strategic-review risk: health information systems alternatives may fail, be abandoned, or remain incomplete
- Most material operational risk: strategic review may divert management attention and create customer and employee uncertainty
- Financial risk: review-related costs may arise regardless of transaction completion
- Near-term performance risk: inability to realize strategic, operational, or financial benefits from any alternative
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Solventum quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.